HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $7 price target.
Intuit Sees Q1 Adj. EPS $0.94-$0.99 vs $1.14 Est.
Intuit announced guidance for the first quarter of fiscal year 2022, which ends Oct. 31. The company expects: Revenue growth of approximately 36 to 38 percent, including Credit Karma. GAAP